The unique metabolic profile of cancer (aerobic glycolysis) might confer apoptosis resistance and be therapeutically targeted. Compared to normal cells, several human cancers have high mitochondrial membrane potential (DJm) and low expression of the K + channel Kv1.5, both contributing to apoptosis resistance. Dichloroacetate (DCA) inhibits mitochondrial pyruvate dehydrogenase kinase (PDK), shifts metabolism from glycolysis to glucose oxidation, decreases DJm, increases mitochondrial H 2 O 2 , and activates Kv channels in all cancer, but not normal, cells; DCA upregulates Kv1.5 by an NFAT1-dependent mechanism. DCA induces apoptosis, decreases proliferation, and inhibits tumor growth, without apparent toxicity. Molecular inhibition of PDK2 by siRNA mimics DCA. The mitochondria-NFAT-Kv axis and PDK are important therapeutic targets in cancer; the orally available DCA is a promising selective anticancer agent.
INTRODUCTION
Cancer progression and its resistance to treatment depend, at least in part, on suppression of apoptosis. Although mitochondria are recognized as regulators of apoptosis, their importance as targets for cancer therapy has not been adequately explored or clinically exploited. In 1930, Warburg suggested that mitochondrial dysfunction in cancer results in a characteristic metabolic phenotype, that is, aerobic glycolysis (Warburg, 1930) . Positron emission tomography (PET) imaging has now confirmed that most malignant tumors have increased glucose uptake and metabolism. This bioenergetic feature is a good marker of cancer but has not been therapeutically pursued, as it
SIGNIFICANCE
The small molecule DCA is a metabolic modulator that has been used in humans for decades in the treatment of lactic acidosis and inherited mitochondrial diseases. Without affecting normal cells, DCA reverses the metabolicelectrical remodeling that we describe in several cancer lines (hyperpolarized mitochondria, activated NFAT1, downregulated Kv1.5), inducing apoptosis and decreasing tumor growth. DCA in the drinking water at clinically relevant doses for up to 3 months prevents and reverses tumor growth in vivo, without apparent toxicity and without affecting hemoglobin, transaminases, or creatinine levels. The ease of delivery, selectivity, and effectiveness make DCA an attractive candidate for proapoptotic cancer therapy which can be rapidly translated into phase II-III clinical trials.
is thought to be a result and not a cause of cancer; that is, the cells rely mostly on glycolysis for energy production because of permanent mitochondrial damage, preventing oxidative phosphorylation. However, whether the mitochondria in cancer are indeed damaged and whether this is reversible remain unknown.
The metabolic hypothesis of cancer has recently been rekindled. Gatenby and Gillies recently proposed that because early carcinogenesis occurs in a hypoxic microenvironment, the transformed cells initially have to rely on glycolysis for energy production (Gatenby and Gillies, 2004) . However, this early metabolic adaptation appears to also offer a proliferative advantage, suppressing apoptosis. Furthermore, the ''byproducts'' of glycolysis (i.e., lactate and acidosis) contribute to the breakdown of the extracellular matrix, facilitate cell mobility, and increase the metastatic potential. Therefore, even though the tumors eventually become vascularized and O 2 levels increase, the glycolytic phenotype persists, resulting in the ''paradox'' of glycolysis during aerobic conditions (the Warburg effect). Metabolic and apoptotic pathways that converge in the mitochondria are not independent from each other, and it appears that glycolytic phenotype is indeed associated with a state of apoptosis resistance (Plas and Thompson, 2002) . Many glycolytic enzymes have been recognized to also regulate apoptosis, and several oncoproteins induce the expression of glycolytic enzymes (Kim and Dang, 2005) . For example, Akt, which stimulates glycolysis and induces resistance to apoptosis (Elstrom et al., 2004) , activates hexokinase, an enzyme catalyzing the first and irreversible step in glycolysis. Via its downstream mediator glycogen synthase kinase 3 (GSK3), Akt induces the translocation of hexokinase to the mitochondrial membrane where it binds to the voltage-dependent anion channel (VDAC), suppressing apoptosis (Kim and Dang, 2005; Pastorino et al., 2005) . Inhibition of GSK3 in cancer cells causes unbinding of hexokinase from VDAC, induces apoptosis, and increases sensitivity to chemotherapy (Pastorino et al., 2005) . This suggests that perhaps the metabolic phenotype in cancer is due to a potentially plastic mitochondrial remodeling that results in suppressed oxidative phosphorylation, enhanced glycolysis, and suppressed apoptosis.
Whether the metabolism of glucose will end with glycolysis in the cytoplasm (converting pyruvate to lactate) or continue with glucose oxidation in the mitochondria is controlled by a gate-keeping mitochondrial enzyme, pyruvate dehydrogenase (PDH) (Figure 1 ). PDH converts pyruvate to acetyl-CoA which, along with the acetyl-CoA from the fatty acid b-oxidation, is fed to the Krebs cycle, producing the electron donors NADH and FADH 2 . NADH donates electrons to complex I of the electron transport chain (ETC) (and FADH 2 to complex III). The flux of electrons down the ETC is associated with production of reactive oxygen species (ROS) (Andersson et al., 2006; Remillard and Yuan, 2004; Wang et al., 2002; Yu et al., 1997 (Caouette et al., 2003) . Furthermore, the mitochondria-derived proapoptotic mediator cytochrome c activates, whereas the antiapoptotic bcl-2 inhibits, Kv channels (Remillard and Yuan, 2004) . This mitochondria-ROS-Kv channel axis is now recognized as a basis of an important O 2 -sensing mechanism in many tissues .
In preliminary experiments, we compared several cancer with normal cell lines and found that cancer cells had more hyperpolarized mitochondria and were relatively deficient in Kv channels. If this metabolic-electrical remodeling is an adaptive response, then its reversal might increase apoptosis and inhibit cancer growth. We used dichloroacetate (DCA), a small, orally available small molecule and a well-characterized inhibitor of PDK (BowkerKinley et al., 1998; Knoechel et al., 2006; Stacpoole, 1989) . As seen in Figure 1 , inhibition of PDK shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation in the mitochondria. The ability of DCA to decrease lactate production has been used for more than 30 years in the treatment of lactic acidosis that complicates inherited mitochondrial diseases in humans (Stacpoole et al., 1988 (Stacpoole et al., , 2006 .
We hypothesized that the downstream effects of the DCA-induced shift in metabolism will have beneficial effects in cancer therapy (Figure 1) . We show that, as predicted, DCA changes the metabolism of cancer cells from the cytoplasm-based glycolysis to the mitochondria-based glucose oxidation. This is associated with increased production of ROS and decreased DJm in all cancer, but not normal, cells, efflux of proapoptotic mediators from the mitochondria, and induction of mitochondria-dependent apoptosis. DCA also reverses the inhibition and downregulation of Kv1.5 in all cancer, but not normal, cells. The resultant efflux of K + , and decrease in intracellular K + , further increases the proapoptotic effects of DCA. DCA effectively decreases tumor growth in vitro and in vivo. We show that a metabolic-electrical remodeling regulates apoptosis resistance in cancer. Moreover, this abnormality is easily reversible by a simple drug that is already used in humans.
RESULTS
Cancer Mitochondria Are Hyperpolarized and Have Suppressed Oxidative Metabolism, Both of which Are Reversed by DCA We studied DJm in three human cancer cell lines: A549 (non-small-cell lung cancer), M059K (glioblastoma), and MCF-7 (breast cancer), and compared them with healthy, noncancerous human cell lines: small airway epithelial cells (SAEC), fibroblasts, and pulmonary artery smooth muscle cells (PASMC). All cancer cell lines had significantly more hyperpolarized DJm compared to normal cells (increased fluorescence of the DJm-sensitive positive dye tetramethyl rhodamine methyl ester; TMRM). Incubation of all three types of cancer cells with DCA (48 hr) reversed the hyperpolarization and returned the DJm to the level of the normal cells (n $ 80 cells, 10 plates/cell line/group). In contrast, DCA did not alter the DJm of the SAEC (Figure 2A) , fibroblasts, and PASMC (not shown). The DCA effects on mitochondrial DJm occurred as quickly as 5 min and were dose dependent ( Figure 2B ). Because the intracellular distribution of TMRM can theoretically be affected by differences in the plasma-membrane potential (Em), we used a protonophore (carbonylcyanide-ptrifluoromethoxyphenylhydrazone; FCCP) and showed that in all cancer cell lines it decreased DJm in a dosedependent manner, eventually depolarizing untreated and In cancer, mitochondrial glucose oxidation is inhibited and energy production relies on the cytoplasmic glycolysis. This ''inactivity'' of the mitochondria likely induces a state of apoptosis resistance. Activation of PDH by DCA increases glucose oxidation by promoting the influx of acetylCoA into the mitochondria and the Krebs cycle, thus increasing NADH delivery to complex I of the electron transport chain, increasing the production of superoxide, which in the presence of MnSOD is dismutated to the more stable H 2 O 2 . Sustained increase in ROS generation can damage the redoxsensitive complex I, inhibiting H + efflux and decreasing DJm. Opening of the DJm-sensitive mitochondrial transition pore (MTP) allows the efflux of cytochrome c and apoptosis inducing factor (AIF ] i on caspases, further enhancing apoptosis. DCA's selectivity is based on its ability to target the unique metabolic profile that characterizes most cancers, and its effectiveness is explained by its dual mechanism of apoptosis induction, both by depolarizing mitochondria (proximal pathway) and activating/upregulating Kv1.5 (distal pathway).
DCA-treated cells at the same low DJm (see Figure S1 in the Supplemental Data available with this article online). This suggests that the TMRM signal was not confounded by DCA effects on the Em, but was rather due to true changes in the DJm.
To determine the effect of DCA on metabolism, we measured glycolysis (Gl), glucose oxidation (GO), and fatty acid oxidation (FAO) in A549 cells (10 plates/experiment, n = 3). DCA significantly increased GO rates (+23%), with a concomitant decrease in both Gl and FAO (Figure 2C ). As expected from the DCA-induced shift of pyruvate metabolism away from lactate and toward acetylCoA and the Krebs cycle, the lactic-acid levels in the culture medium of the DCA-treated cells decreased ( Figure 2D , n = 10 plates/group) and the intracellular pH increased ( Figure 2E , n = 5 plates, 60 cells/group).
DCA Causes Efflux of Proapoptotic Factors from Mitochondria and Increases ROS Production
Whereas the untreated cancer cells (A549) showed cytochrome c and apoptosis-inducing factor (AIF) restricted to the mitochondria (colocalized with mitotracker red), in the DCA-treated cells cytochrome c was diffusely present in the cytoplasm and AIF was translocated to the nucleus ( Figure 3A) , both indicating induction of apoptosis.
DCA increased H 2 O 2 production in a dose-dependent manner; this increase was inhibited by rotenone, suggesting that it was based on complex I of the ETC ( Figure 3B , n = 5 plates/group). We also measured NADH levels in isolated mitochondria and showed that DCA increased the intramitochondrial NADH ( Figure 3C , 5 plates/experiment, n = 5). The DCA-induced decrease in DJm was limited by the VDAC (an important component of the mitochondrial transition pore; MTP) inhibitor 4 0 -diisothiocyano-2,2 0 -disulfonic acid stilbene (DIDS; 0.5 mM) (Granville and Gottlieb, 2003) (Figure 3D , n = 5, $60 cells/ group).
To determine whether cancer cells are less dependent on the ETC and oxidative phosphorylation, we studied the effects of low-dose cyanide (a complex-IV inhibitor and a well-known poison for normal cells). Cyanide's effects on mitochondria (as measured by DJm) were much less pronounced in cancer compared to the DCAtreated cells ( Figure 3E , n = 5, $60 cells/group).
DCA Activates Kv Channels in Cancer Cells by an H 2 O 2 -Dependent Mechanism
Using whole-cell patch clamping, we showed that in all untreated cancer cell lines the outward K + current (Ik) was small and essentially voltage independent. DCA increased the Ik significantly in all cancer cell lines, but did not alter the Ik in the noncancerous SAEC ( Figure 4A ), PASMC, or fibroblasts (not shown) ( Figure 4A , n = 7-8/ group). The increase in Ik occurred as early as 5 min and persisted after 48 hr of DCA exposure. Most of the increased Ik was voltage dependent and blocked by 4-aminopyridine, a specific Kv channel inhibitor. The increased Ik caused hyperpolarization of the plasmamembrane Em. DCA also decreased cell capacitance, an electrophysiologic surrogate of cell size/volume, consistent with the cell shrinkage that characterizes early apoptosis ( Figure 4A ). The DCA-induced increase in Ik was blocked by intracellular catalase, delivered through the patch pipette (i.e., due to H 2 O 2 ), and by rotenone (i.e., due to complex I-produced H 2 O 2 ), but not by thenoyltrifluoroacetone Only one study has linked Kv1.5 with cancer: Kv1.5 expression (but not other Kv channels) correlates with tumor grade in human gliomas, that is, the higher the grade, the lower the Kv1.5 (Preussat et al., 2003) . We used quantitative real-time polymerase chain reaction (n = 5) and immunoblots and showed that Kv1.5 is significantly increased in DCA-treated A549 cancer cells ( Figure 4D ), in contrast to Kir2.1, a K + channel from a different family (not shown).
To study whether Kv1.5 expression correlates with human tumor grade, we used archived tumors from a cohort of 30 consecutive patients with non-small-cell lung cancer. We measured both Kv1.5 and survivin expression in each tumor sample and correlated their levels with histologic tumor grade by blinded readers. Survivin, a marker of resistance to apoptosis and tumor aggressiveness, has recently been shown to regulate mitochondria-dependent and MCF-7) but does not affect noncancerous SAEC. On the left, original traces representing the K + current in both untreated and DCA-treated cells are shown. The increase in K + current density is mainly due to an increase in Kv current, as most of the increased current is 4-aminopyridine sensitive.
Current subtraction was performed and the DCA-induced Kv current is shown in the insets. DCA treatment also causes a significant decrease in membrane capacitance and an increase in the plasma-membrane resting potential (*p < 0.05 versus control).
(B) The mechanism by which DCA increases K + current was assessed by exposing cancer (A549) cells to DCA (0.5 mM) acutely (5-10 min). The effects of DCA on K + current were blocked by 4-aminopyridine (5 mM), catalase (10,000 units, intracellularly via pipette), and rotenone (5 mM), whereas a specific blocker of complex II (TTFA, 1 mM) did not alter the DCA effects (*p < 0.05 versus control). apoptosis in both cancer (Dohi et al., 2004) and vascular tissues (McMurtry et al., 2005) . Survivin correlated positively with tumor grade while Kv1.5 correlated negatively (the higher the Kv1.5, the lower the grade), and no differences in the expression of Kir2.1 were seen ( Figure S2 ). Because NFAT (nuclear factor of activated T lymphocytes) inhibits both apoptosis (Pu et al., 2003) and the expression of Kv1.5 in myocardial cells (Rossow et al., 2004) , we speculated that this could also occur in cancer. Increases in [Ca 2+ ] i activate calcineurin, which dephosphorylates NFAT, allowing its translocation to the nucleus where it regulates gene transcription (Macian, 2005 ] i in the DCA-treated cells is inhibited by lanthanum (n = 6), a blocker of Ca 2+ entry into the cell ( Figure 5A ), confirming an operative voltage-dependent pathway of Ca 2+ entry.
NFAT1 activation (defined by its translocation to the nucleus) is evident in the majority of untreated A549 cells, and in these cells Kv1.5 expression is low ( Figure 5B ). In contrast, in DCA-treated cells, NFAT1 is mostly cytoplasmic and Kv1.5 expression is proportionately increased. As with Ik ( Figure 4B ) and [Ca 2+ ] i ( Figure 5A ), the effects of DCA on NFAT1 were mimicked by t-butyryl-H 2 O 2 ( Figure 5B ). We then treated A549 cells with VIVIT, a competing peptide that selectively blocks NFATregulated mechanisms due to its ability to block calcineurin docking on NFAT, preventing its activation without inhibiting calcineurin's catalytic site (Aramburu et al., 1999) . The VIVIT-treated cells show displacement of NFAT1 from the nucleus and increased Kv1.5 expression ( Figure 5B ). The same was true for cells treated with cyclosporine, a nonspecific inhibitor of calcineurin ( Figure S3A ).
In human non-small-cell lung tumors costained with anti-Kv1.5, anti-NFAT1, and 4 0 ,6-diamidino-2-phenylindole (DAPI), low-grade histology was associated with high Kv1.5 expression and low NFAT1 expression, most of which was cytoplasmic; the reverse pattern was seen in high-grade tumors ( Figure 5C ).
The effects of NFAT1 might be potentiated by a positive feedback loop: low Kv1.5 / depolarized plasma membrane / Ca 2+ influx / high [Ca 2+ ] i / activated NFAT / low Kv1.5. NFAT inhibition effectively breaks this loop because VIVIT decreases [Ca 2+ ] i (n = 5 plates/ group, Figure 5D ).
DCA Induces Mitochondria-Dependent Apoptosis and Decreases Proliferation In Vitro DCA increases annexin expression, causes a $6-fold increase in the percentage of TUNEL-positive nuclei, and activates both caspase 3 and 9 in A549 cells (Figures 6A and 6D) . Figure 4 ). 4-aminopyridine decreases DCA-induced apoptosis by $32% (also see Figure S4 ). *p < 0.05 versus controls.
In addition, DCA decreases the expression of survivin ( Figure 6B ). DCA-induced apoptosis proceeds by two pathways, one in the mitochondria, where depolarization activates mitochondria-dependent apoptosis, and the other at the plasmalemmal level, where activation/upregulation of Kv1.5 channels decreases [K + ] i , activating caspases. To determine the relative importance of the two mechanisms, we compared the apoptosis induced by DCA to the apoptosis induced by a primary increase in Kv1.5 expression, using adenoviral gene transfer ( Figures 6C and 6D ). Compared to the adenovirus carrying green fluorescent protein (GFP) only, the adenovirus carrying GFP and cloned human Kv1.5 (Pozeg et al., 2003) significantly increased the percentage of TUNEL-positive cells. However, although the increase in Ik achieved with the gene transfer was higher than the increase achieved by DCA ( Figure 6C ; compare with Figure 4A ), the increase in apoptosis achieved by the gene transfer was significantly less than that achieved by DCA ( Figure 6D ). We then measured the DCA-induced apoptosis in the presence of 4-aminopyridine (5 mM), a blocker of the whole Kv family. In addition to the A549 cells we also studied glioblastoma, an excitable cell type in which Kv channels might be more important in apoptosis regulation compared to the epithelial A549 cells. In the presence of 4-aminopyridine, DCA induced 68% of the apoptosis (% TUNEL-positive cells) induced by DCA alone ( Figure 6D ). Similarly, in glioblastoma cells, DCA + 4-aminopyridine induced 62% of the apoptosis induced by DCA alone ( Figure S4 ). Moreover, 4-aminopyridine did not limit DCA's ability to cause efflux of cytochrome c from mitochondria, initiating mitochondriabased apoptosis ( Figure S4 ). These data underlie the preponderant importance of the mitochondrial component of DCA's proapoptotic actions.
That NFAT1 is a distal mediator in DCA's anticancer effects was supported by the fact that VIVIT increased apoptosis and decreased proliferation in a manner similar to DCA ( Figure S3B ). For imaging studies, we studied four random fields per slide for $30 slides/group, and for patch clamping, 6-8 cells/group.
Molecular Inhibition of PDK2 Mimics DCA
To confirm that inhibition of PDK is the major mechanism for the effects of DCA, we determined whether molecular inhibition of PDK2 by siRNA mimics DCA. We chose PDK2 because it is the only ubiquitously expressed isoenzyme; PDK1 and 3 are restricted in the heart and testis, respectively, and PDK4 is mostly expressed in skeletal muscle and heart. PDK2 is the most active of all and also has the lowest Ki for DCA (0.2 mM) (Bowker-Kinley et al., 1998). siRNA for PDK2 inhibited the expression of PDK2 in a dose-dependent manner, inhibiting mRNA up to 80% and protein expression (measured by both immunoblots and immunohistochemistry) by $70% ( Figure S5 ). We tested three commercially available PDK2 siRNAs, which all inhibited the gene in a similar manner. Scrambled siRNA for PDK2 as well as siRNA for PDK1 did not decrease PDK2 expression ( Figure S5 ). Whereas the scrambled siRNA had no effect on A549 cells, PDK2 siRNA decreased DJm and increased mitochondrial ROS in a manner identical to DCA ( Figures 7A and 7B , n $ 20 plates/group). DCA added to siRNA-treated cells had no additional effects (data not shown). Inhibition of PDK2 by siRNA also increased apoptosis and decreased proliferation in cancer cells (Figure 7C , n $ 30 plates/group). To further prove that DCA activates PDH by inhibiting PDK, we immunoprecipitated PDH and showed that DCA increased the nonphosphorylated fraction (i.e., active) of the catalytic subunit (E1a) ( Figure 7D ).
DCA in the Drinking Water Induces Apoptosis and Decreases Tumor Growth In Vivo
We studied nude athymic rats implanted subcutaneously with 3 3 10 6 A549 cells. The rats had free access to water with or without DCA (75 mg/l). In the first set of experiments (protocol a), 21 animals were divided into three groups: untreated controls (n = 5), DCA-prevention rats (n = 8), which received DCA just after cell injection for 5 weeks, and DCA-reversal rats (n = 8), which received DCA 2 weeks post-cell injection for 3 more weeks. The untreated rats rapidly developed tumors with a constant exponential tumor growth ( Figure 8A ). Both DCA-treated groups had a significant decrease in tumor size, measured by tumor weight at sacrifice and maximal diameter using calipers; in some rats, in vivo magnetic resonance imaging allowed us to visualize the tumors in vivo and calculate their volume. The decrease in tumor growth by DCA was associated with an increase in apoptosis (TUNEL) and a decrease in proliferation (PCNA) ( Figure 8B ). There was an inverse correlation between apoptosis and tumor size in the treated rats ( Figure 8B ). Kv1.5 was upregulated and survivin was downregulated in the DCA-treated rats ( Figure 8C ), confirming our in vitro data (Figures 4  and 6) . In a second set of experiments (protocol b), we studied whether the effects of DCA were sustained for longer periods of time and whether DCA would have a similar effect in more advanced tumors. We followed three groups of rats (n = 6/group) for 12 weeks: an untreated control group, a prevention group (rats given DCA at the time of tumor cell injection), and a reversal group where rats were given DCA at week 10 for 2 weeks. As in protocol a, at all times rats in the prevention group had significantly smaller tumors compared to the untreated controls; DCA at week 10 inhibited tumor growth immediately, with a significant decrease even after 1 week of treatment. DCA therapy did not have any toxic effects, as measured by several blood tests ( Figure 8D ; also see McMurtry et al., 2004) .
DISCUSSION
Here we show that a metabolic-electrical remodeling (hyperpolarized mitochondria, downregulated Kv channels) regulates the apoptosis resistance that characterizes multiple human cancers. DCA, a small molecule that targets mitochondria, reverses this remodeling, inducing
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Cancer Cell apoptosis and decreasing cancer growth in vitro and in vivo. These beneficial effects occur without affecting noncancerous cells or eliciting systemic toxicity. DCA treatment significantly increases glucose oxidation (which only occurs in functional mitochondria), indicating that the well-recognized, metabolic cancer signature (aerobic glycolysis) is reversible, rather than a consequence of permanent mitochondrial damage. DCA exerts its beneficial effects by two pathways, both of which induce apoptosis: first, by mitochondrial depolarization and efflux of proapoptotic mediators, and second, by an increase in Kv channel expression/function. DCA increases Kv channel expression by inhibiting NFAT1, a calcium-sensitive transcription factor that regulates cell-differentiation programs in many cell types but which has previously been unexplored in cancer. The mitochondria-NFAT-Kv pathway in cancer offers several new candidate targets for proapoptotic therapy that would be predicted to have high therapeutic selectivity.
Glycolysis and Cancer: Not Just an Epiphenomenon
It is now well accepted that most cancers have a glycolytic phenotype. Warburg suggested, but did not prove, that this was due to ''abnormal mitochondria'' (Warburg, 1930) ; that is, cancer cells are forced to use inefficient, nonmitochondrial means of generating ATP. Our data suggest that this apparent mitochondrial ''dysfunction'' is in fact reversible. Oxidative metabolism in cancer could be actively suppressed; the resultant shift to glycolysis may lead to apoptosis resistance (Plas and Thompson, 2002) , offering Figure S1 ) depolarizes A549 mitochondria in a manner similar to DCA, whereas scrambled siRNA has no effect. (B) siRNA inhibition of PDK2 also mimics DCA in increasing mitochondria-derived ROS, as measured with the fluorescent dye mitosox. (C) siRNA inhibition of PDK2 increases apoptosis (% TUNEL-positive cells), similar to DCA. (D) Human PDH was immunoprecipitated from A549 cells and treated with a cocktail of monoclonal antibodies against several PDH subunits. In the untreated cancer cells, the E1a subunit (i.e., the catalytic subunit) is all in the phosphorylated form, indicating maximal inhibition of PDH by PDK. In the DCA-treated cells, the nonphosphorylated fraction of the E1a subunit is significantly increased, indicating an increase in the activity of PDH. *p < 0.05 versus controls. a survival advantage in the transformed cells (Gatenby and Gillies, 2004) . This suggests that a novel way to reverse apoptosis resistance might be to undo this metabolic/mitochondrial remodeling. We show that the glycolytic phenotype in cancer is easily altered by promoting oxidative phosphorylation ( Figure 2C ). This is associated with mitochondrial depolarization, which facilitates apoptosis and inhibits tumor growth. All the human cancer cell lines studied had more negative DJm compared to several noncancerous cell lines (Figure 2A ), suggesting that this might be a hallmark of malignancy. Although apoptosis is not always associated with mitochondrial depolarization, our data are in agreement with the observation that cationic lipophilic drugs preferentially accumulate to tumor mitochondria (Don and Hogg, 2004) . In addition, the positively charged rhodamine-based dyes (like TMRM) have been tried as ''carriers'' for selective delivery of drugs in cancer.
More than 200 carcinomas were screened and were shown to accumulate rhodamine much more than noncarcinoma cells; these findings were first reviewed in 1988 (Chen, 1988) , and although the mechanism was not clear then, it likely reflects the more negative DJm of cancer compared to noncancerous cells. Our work directly shows that this relative increase in DJm is associated with increased resistance to apoptosis, and its ''normalization'' increases apoptosis and decreases cancer growth. Furthermore, it has just been shown that DJm of colon cancer cells predicts the aggressiveness of the tumor cells, that is, the more hyperpolarized the DJm, the more aggressive and metastatic the tumor (Heerdt et al., 2005) , in agreement with our proposal. Studying DJm in fresh tumor specimens might be a convenient means to predict resistance to proapoptotic chemotherapies, with important implications in clinical decision making. How Does DCA Alter Metabolism, Depolarize Mitochondria, and Initiate Apoptosis? The shift in the metabolism of pyruvate away from lactate and toward acetyl-CoA and the Krebs cycle ( Figures 2C  and 2D ), caused by DCA or molecular inhibition of PDK2 (Figure 7) , increases the intramitochondrial production of the electron-donor NADH ( Figure 3C ), a substrate of the ETC complex I, leading to increased complex I-based ROS production ( Figures 3B and 7B) (Kushnareva et al., 2002) . A sustained increase in the ROS production can cause oxidative damage in the ETC, particularly complex I. This megacomplex is the most sensitive of all ETC complexes to ROS damage because it is by far the largest (46 subunits), and has at least nine ROS-sensitive iron-sulfur centers and seven mitochondrial DNA-encoded subunits (Brandt, 2006) , which are very susceptible to oxidative damage. The ROS-induced complex-I dysfunction can limit the efflux of H + , decreasing DJm. Upon sustained and significant decrease in DJm, the voltage-sensitive MTP opens (Zamzami and Kroemer, 2001) , allowing the efflux of many proapoptotic factors and the initiation of apoptosis ( Figures 3A, 6 , and 8B). This further increases the production of mitochondrial ROS, likely reinforcing a positive feedback loop enhancing apoptosis (Zamzami and Kroemer, 2001 ).
This ''complex I-centered'' proposed mechanism has a precedent in congenital mitochondrial syndromes and neurodegenerative diseases. Patients with congenital complex-I deficiency have decreased DJm and increased ROS production (Pitkanen and Robinson, 1996) . Inhibition of complex I in cell lines is associated with decreased DJm and increased ROS production in a dose-dependent manner, that is, the higher the percent complex-I inhibition, the higher the ROS and the lower the DJm (Barrientos and Moraes, 1999) . A similar mechanism where dose-dependent inhibition of complex I leads to dose-dependent efflux of cytochrome c and apoptosis (Clayton et al., 2005) is proposed in the pathogenesis of neurodegenerative diseases such as Parkinson's, where complex-I dysfunction and ROS-mediated oxidative damage are well described (Bao et al., 2005; Schon and Manfredi, 2003) .
Inhibition of VDAC limited the DCA-induced decrease in DJm ( Figure 3D ). VDAC (along with the adenine nucleotide translocase) is involved in the translocation of ADP (a substrate for the F1F0-ATPase) from the cytoplasm into the mitochondria. Inhibition of the VDAC would thus inhibit the function of the F1F0-ATPase, which would lead to accumulation of H + in the intermembrane mitochondrial space, promoting hyperpolarization of the DJm, thus limiting the depolarizing effects of DCA. This is supported by findings from Thompson's group (Vander Heiden et al., 1999) , although the role of VDAC in the regulation of DJm and initiation of apoptosis remains controversial (Shimizu et al., 1999 ) (reviewed in Granville and Gottlieb, 2003) , and some of these mechanisms might only be relevant to specific experimental conditions, such as growth-factor withdrawal (Vander Heiden et al., 1999 ). An additional intriguing possibility is that, because DCA is itself an anion (see structure in Figure 1) , it likely enters the mitochondria via the VDAC, explaining, at least in part, why its inhibition limits the effects of DCA on DJm.
Unexpectedly, but consistent with its therapeutic benefit, DCA decreased the expression of survivin, an inhibitor of apoptosis, both in vitro and in vivo (Figures 6 and 8) . Survivin has recently emerged as a major antiapoptotic oncoprotein. The mechanism by which survivin is downregulated is unclear. Recent observations describing the direct involvement of a mitochondrial survivin pool in the suppression of apoptosis suggest that survivin might participate in the mitochondrial remodeling of cancer (Dohi et al., 2004; McMurtry et al., 2005) . ] i which increases the tonic inhibition that cytosolic K + exerts on caspases. Kv1.5 gene transfer directly activated apoptosis in A549 cells (Figures 6C and 6D) . Functional inhibition of all Kv channels by 4-aminopyridine limited the DCA-induced apoptosis by $32% in A549 cells and by $38% in glioblastoma cells ( Figure 6D ; Figure S4 ), suggesting that although the majority of apoptosis in DCA-treated cells is a direct result of efflux of proapoptotic mediators from cancer cells, the secondary effects on Kv channels also play an important role.
The precise role of K + channels in cancer remains unclear, and although K + channel opening promotes apoptosis in several tumors, the opposite result has also been noted (reviewed in Wang, 2004) . Perhaps this relates to the type of tumor or the well-known diversity of K + channel families. Specific K + channels are now emerging as important regulators of apoptosis in different cell types. For example, HERG, a Kv channel, mediates H 2 O 2 -dependent apoptosis in various cancer cell lines (i.e., low HERG expression reduces apoptosis and enhances proliferation) (Wang et al., 2002) . Kv1.5 regulates apoptosis in PASMC (Remillard and Yuan, 2004) and is downregulated in the proliferative and apoptosis-resistant vascular media in pulmonary hypertension (McMurtry et al., 2004 (McMurtry et al., , 2005 Pozeg et al., 2003) . A teleological advantage of Kv1.5 as a regulator of apoptosis in cancer, and a factor which focused our attention on this channel, is its very short turnover time, less than 8 hr from transcription to functional expression (Levitan et al., 1995) . We show that cancer cells are deficient in ETC complex I-based production of H 2 O 2 , a Kv1.5 channel opener (Figure 3B) . Perhaps more importantly, Kv1.5 is downregulated in cancer cell lines ( Figure 4D ), and Kv1.5 expression correlates inversely with histologic grade in a cohort of patients with non-small-cell lung cancer (more aggressive tumors have less Kv1.5) ( Figure S2 ). We have identified NFAT1 as an important transcription factor responsible for this Kv1.5 downregulation (more aggressive cancers have more activated NFAT1) ( Figure 5C ).
The cellular environment in cancer is favorable for NFAT activation. A549 cells have increased [Ca 2+ ] i ( Figure 5A ), a direct activator of calcineurin and thus NFAT (Macian, 2005) . This increase in [Ca 2+ ] i is, at least in part, due to the increased Ca 2+ influx that results from the Kv channel deficiency (Figure 4 ). In addition, calcineurin is inhibited by increased ROS levels (Namgaladze et al., 2005) ; thus, the low mitochondrial ROS in cancer ( Figures 3B and 7B ) promote NFAT activation. Furthermore, the acidotic environment in cancer (due to aerobic glycolysis) ( Figure 2E ) would further promote NFAT activation (Komarova et al., 2005) . It is remarkable that all of these mechanisms are reversed by DCA, which increases ROS, increases pH, and decreases [Ca 2+ ] i , explaining its impressive effects on NFAT ( Figure 5B ). The upregulation of Kv1.5 by a drug that directly affects mitochondrial function suggests the presence of the mitochondria-NFAT-Kv1.5 axis, which is suppressed in cancer. Our work suggests that potential effects on Kv channels should be considered in cancer therapies targeting the mitochondria.
Metabolic Modulation in Cancer by DCA: Possibility of Prompt Translation to Clinical Oncology
Our work suggests that metabolic modulators could be beneficial in human cancer, either alone or in combination with traditional chemotherapies, as apoptosis sensitizers. By targeting a fundamental and unique property of cancer cells, this approach may combine efficacy and selectivity. DCA (in clinically relevant doses; Stacpoole et al., 2006) was effective in preventing and inhibiting tumor growth in established tumors both early (week 2) and late (week 10) in their development ( Figure 8A ). DCA's effects in the reversal protocols were immediate, with significant effects even after 1 week of treatment. The relative specificity of DCA to target a metabolic (mitochondria) and electric (K + channels) remodeling was confirmed by microarray experiments, where pathway analysis revealed a short list of altered mitochondrial apoptosis cell cycle and ion channel genes (Supplemental Results; Figure S6) .
A very attractive property of DCA is its selectivity, evident by the lack of any systemic toxicity in this (Figure 8D ) and other recent animal (McMurtry et al., 2004) and human studies (Stacpoole et al., 2006 ). DCA's ability to ''restore'' DJm might explain why it is effective preferentially in cells that have very high DJm, such as cancer cells, but has no effects in normal cells (epithelial, fibroblasts, or PASMC). Preferential expression of PDK might also contribute to its selectivity. In a recent study of nonsmall-cell lung cancer specimens, cancer cells had increased PDK2 and decreased PDH expression (compatible with a glycolytic phenotype) compared to neighboring nonmalignant cells (Koukourakis et al., 2005) .
The small size of DCA results in excellent tissue penetration after oral intake, including the central nervous system (Stacpoole et al., 2003) , relevant to the difficult-to-treat glioblastoma, one of the tumors that we studied in vitro. In addition, DCA decreases tumor lactic-acid production and increases intracellular pH ( Figure 2E) ; future studies need to address the hypothesis that this will decrease tumor invasiveness and metastatic potential (Gatenby and Gillies, 2004) .
Our work identifies the mitochondria-NFAT-Kv channel axis and PDK as critical components of the metabolicelectrical remodeling that characterizes many human cancers and offers a tantalizing suggestion that DCA may have selective anticancer efficacy in patients. The very recent report of the first randomized long-term clinical trial of oral DCA in children with congenital lactic acidosis (at doses similar to those used in our in vivo experiments) showing that DCA was well tolerated and safe (Stacpoole et al., 2006) suggests a potentially easy translation of our work to clinical oncology.
EXPERIMENTAL PROCEDURES
The use of human tissues was approved by the University of Alberta Human Ethics Committee, and all experiments with rodents were approved by the University of Alberta Animal Ethics Committee (Health Sciences Laboratory Animal Services).
Confocal Microscopy
Imaging was performed using a Zeiss LSM 510 multiphoton confocal microscope (Carl Zeiss Canada, Toronto, ON) and multiple-staining techniques, as previously described (McMurtry et al., 2004 (McMurtry et al., , 2005 . For details, see Supplemental Data.
Metabolic Studies A549 cells were grown to confluency in T-175 flasks and rates of glycolysis, fatty acid oxidation, and glucose oxidation were measured as previously described (Saddik et al., 1993) in the presence or absence of DCA (0.5 mM, 48 hr); also see Supplemental Data.
Ca

2+ Measurements
Intracellular free Ca 2+ concentration ([Ca 2+ ] i ) was studied in live A549
cancer cells using FLUO-3AM (Invitrogen-Molecular Probes Canada, Burlington, ON). Cells were loaded with FLUO-3AM (5 mmol/l) for 45 min (37 C) in serum-free medium and washed for 30 min in PBS (37 C) to allow cleavage of the acetoxymethyl esters. In association with FLUO-3, Hoechst (1.0 mmol/l) nuclear staining was applied for 10 min (Molecular Probes). Fluorescence was measured at 505-535 nm with excitation at 488 nm.
H 2 O 2 Measurements
Cancer cells were propagated on LabTek multiwell slides (Nalge Nunc, Rochester, NY, USA; VWR, Mississauga, ON, Canada) until confluent. Monolayers were preincubated with DCA in the presence or absence of 5 mM rotenone (Sigma-Aldrich Canada, Oakville, ON) for 1 hr. Production of H 2 O 2 was measured by the AmplexRed assay (Molecular Probes). Fluorescence was measured at 590 nm with excitation at 530 nm, and H 2 O 2 levels were determined by reference to a standard curve, as previously described (McMurtry et al., 2004) .
Electrophysiology
With standard whole-cell patch-clamping techniques, cells were voltage clamped at a holding potential of À70 mV and currents were evoked by 200 ms test pulses from À70 to +70 mV with 20 mV steps, filtered at 1 kHz, and sampled at 2-4 kHz, as previously described (McMurtry et al., 2004 (McMurtry et al., , 2005 .
Immunoblotting and Quantitative Real-Time Polymerase Chain Reaction For details, antibodies, and primers, see Supplemental Data.
Kv1.5 Gene Transfer A549 cells were infected with replication-deficient serotype-5 adenovirus encoding genes for GFP and cloned human Kv1.5 (both under cytomegalovirus [CMV] promoters) as previously described (McMurtry et al., 2005; Pozeg et al., 2003) . We achieved 80% infection rates, and infected cells were selected on the basis of their green fluorescence.
In Vivo Tumorigenicity Assays A cell suspension of A549 cells in PBS (3 3 10 6 cells per injection) was injected subcutaneously into nude athymic rats. Rats were divided into control (no treatment), prevention, and reversal groups, and two protocols were followed. In protocol a, rats were followed for 5 weeks: the prevention group was treated for 5 weeks and the reversal group for 3 (weeks 3-5). In protocol b, rats were followed for 12 weeks, with the prevention group treated for 12 weeks and the reversal group from week 10 to week 12. In both protocols, DCA (0.075 g/l) was added to the drinking water. By measuring the amount of water consumed, we calculated and adjusted the concentration of DCA required to achieve a daily dose similar to that used clinically (50-100 mg/kg) (McMurtry et al., 2004; Stacpoole et al., 2006) Rats were observed weekly for the appearance of tumors at injection sites, and tumor size was measured every week with calipers in the three groups. Mitochondrial NADH Mitochondria were isolated from both untreated and DCA-treated cells (500 mM, 48 hr), as previously described (Michelakis et al., 2002) . Mitochondrial NADH ([NADH]m) was assessed using the methods described previously by Brandes and Bers (1996) . The mitochondria were excited by light at 350 nm, and fluorescence was detected at 456 nm using a Photon Technology International Delta Scan 1 fluorescence spectrophotometer (London, ON, Canada). The fluorescence signal at 456 nm is known to predominantly arise from [NADH]m (Eng et al., 1989) .
PDH Activity PDH activity was assessed by measuring the amount of phosphorylated and unphosphorylated E1a subunits. Three milligrams of protein was isolated from untreated and DCA-treated cells. PDH subunits were isolated using the PDH complex immunocapture kit (MitoSciences, Eugene, OR, USA). The immunoprecipitated fraction was then used for immunoblotting using the human PDH subunits monoclonal antibody cocktail (MitoSciences).
siRNA Studies A549 lung cancer cells were grown to 80% confluence in six-well culture dishes. The transfection agent siPORTamine (Ambion siRNA Transfection II kit 1631, Ambion, Austin, TX) was preincubated at room temperature for 10 min at a ratio of 1:12 in OptiMEM1 culture medium (Invitrogen-GIBCO Canada, 31985-070, Burlington, ON). This concentration of transfection agent had previously been demonstrated to result in at least 60% gene knockdown with less than 15% cell death (data not shown). The mixture was combined with 75, 37.5, or 18.7 nmol of scrambled versus silencer RNA for human PDK2 and PDK1 (Ambion) in an equivalent volume of OptiMEM1, and incubated for a further 10 min. The PDK2 silencer variants ID 264, 265, and 266 were also tested. The culture medium was aspirated from the cells, the transfection agent-RNA complex mixture was allowed to spread over the monolayer, and 1.5 ml of complete F12K was added. Plates were incubated at 37 C for 48 hr. 
Cell Cultures
